Review Article
Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting
Table 1
Examples of multifunctional liposomal nanocarriers.
| Encapsulated agent | Targeting ligand | Development stage | References |
| Doxorubicin | None | Approved (Doxil/Caelyx) | [13] | Vincristine | None | Approved (Marqibo) | [14] | Paclitaxel | None | Approved (Lipusu) | [15] | Cytarabine and daunorubicin | None | Phase I (CPX-351) | [24] | Irinotecan and floxuridine | None | Phase I (CPX-1) | [25] | PKN3 siRNA | None | Phase I (Atu-027) | [26] | Irinotecan | None | Phase I (NL CPT-11) | [27] | Doxorubicin | Stomach cancer-specific anti-GAH mAb | Phase I (MCC-465) | [28] | Oxaliplatin | Transferrin | Phase II (MBP-426) | [29] | Liposomal p53 DNA and docetaxel | Anti-Transferrin receptor scFv | Phase I (SGT53-01) | [30] | Doxorubicin | Thermoresponsive liposomes | Phase III (ThermoDox) | [31] | Doxorubicin | Cancer-specific 2C5 mAb | preclinical | [32] | Doxorubicin | Anti-CD22 mAb | preclinical | [33] | Paclitaxel | Anti-HER2 mAb | preclinical | [34] | Vincristine | mBAFF | preclinical | [35] | Oxaliplatin | Transferrin | preclinical | [36] | Daunorubicin | Transferrin and mannose | preclinical | [37] | Vinorelbine | NSCLC-specific peptide | preclinical | [38] | Doxorubicin | Metastasis-specific peptide | preclinical | [39] | Doxorubicin | MMP-2/9 detachable PEG | preclinical | [40] | Irinotecan | Folic acid | preclinical | [41] | Doxorubicin | Estrone | preclinical | [42] | Etoposide | Chondroitin sulfate | preclinical | [43] |
|
|